Oncology & Cancer

PFS up with obinutuzumab-based Tx in follicular lymphoma

(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

Oncology & Cancer

FDA approves aliqopa for follicular lymphoma

(HealthDay)—Aliqopa (copanlisib) has been approved by the U.S. Food and Drug Administration to treat adults with relapsed follicular lymphoma who have received at least two prior treatments with certain other drugs.

Oncology & Cancer

Follicular lymphoma: A tale of two cancers

Follicular lymphoma (FL), the second most common form of non-Hodgkin lymphoma, is a largely incurable disease of B cells, yet in many cases, because of its indolent nature, survival can extend to well beyond 10 years following ...

Diseases, Conditions, Syndromes

Bacterium that causes Q fever linked to non-Hodgkin lymphoma

The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American ...

Oncology & Cancer

Researchers define unique group of high-risk lymphoma patients

The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular ...

page 2 from 5